NewsRoom Articles - Page 58 of 154 - PsychedelicNewsWire (PNW)

FridayMay 27, 2022 1:35 pm

VC Executive Shares Insights into Legal Psychedelics Landscape

These past few years, an increasing number of studies on psychedelics have been conducted, with researchers finding that these substances may be used as alternative treatments for mental health conditions such as depression and anxiety. The latest data from World Health Organization shows that the international prevalence of depression and anxiety increased by roughly 25% in the first year of the coronavirus pandemic, and drugs such as psilocybin, MDMA and ketamine are now being studied to develop treatments for everything from depression to PTSD. In a recent interview, some specialized VC’s were asked to give their insights into the psychedelic…

ThursdayMay 26, 2022 1:42 pm

How Psychedelic Treatments Can Become Accessible, Affordable

As the psychedelic industry continues to grow and more is discovered about these compounds and the benefits they hold, concern about whether these treatments will be affordable by the general public increase as well. Last week, Imperial College London research associate Balázs Szigeti stated on Twitter that the lengthy hours needed for psychedelic-assisted therapy would increase the cost of these treatments, making this treatment option more expensive than SSRI treatments, which are cheaper and widely available. This sparked a discussion on what could be done to make psychedelic-assisted therapy equitable and affordable, with safe supply, commercialization, having trained professionals and…

ThursdayMay 26, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds

Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disorders Participants given psilocybin therapy reported a rapid, sustained improvement in their depression Cybin’s CYB003 has demonstrated less variability, faster onset, shorter duration and better brain penetration than oral psilocybin A new study sponsored by Imperial College London reports that psychedelic compounds may be effective in treating mental-health disorders (https://ibn.fm/xSdZv). The study supports efforts made by Cybin (NEO: CYBN) (NYSE American: CYBN), which is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental-health disorders.…

WednesdayMay 25, 2022 3:11 pm

Davos Hosts Psychedelic Medical Series

With increasing evidence suggesting that psychedelic-assisted therapy may be useful in the treatment of various mental health conditions, including post-traumatic stress disorder, substance-abuse disorders and depression, the emphasis on mental health treatment has grown these last few years. This has been fueled by the fallout of the coronavirus pandemic and the current war in Ukraine. The annual meeting of the World Economic Forum is taking place this week in Davos-Klosters, Switzerland. At the event, top financial and political leaders in the world gather to discuss how to improve the state of the world. Coincidentally, the biggest names in the psychedelics…

TuesdayMay 24, 2022 11:59 am

CSIRO to Collaborate with Biotechnology Firms on Psychedelic Research

The Commonwealth Scientific and Industrial Research Organization (CSIRO), which is the national science agency of Australia, is planning to collaborate with local medical technology firms to develop new psychedelic products while also improving the existing products. The agency’s objective is to develop new psychedelics to help individuals suffering from various mental health conditions, including post-traumatic stress disorder, end-of-life anxiety, addiction and depression. There are many psychedelics in existence, both synthetic and natural alike. CSIRO plans to work with local biomedical firms to extract, synthesize, improve and develop manufacturing processes for up to 15 different psychedelic compounds. Psilocybin is the active…

MondayMay 23, 2022 12:17 pm

Health Canada Gives First Quebec Patient Nod for Psilocybin Therapy

In January, Health Canada made the process of accessing legal psilocybin-psychotherapy for mental health conditions easier for patients. Psilocybin is the active compound found in magic mushrooms. Thomas Hartle, a 54-year-old suffering from terminal colon cancer, is one of the patients who has benefited from this. Hartle undergoes psilocybin treatment for the management of his end-of-life anxiety, which was brought on by his terminal illness diagnosis. He is one of the few individuals in Canada who have received legal psychedelic therapy since Health Canada made it possible to do so by restoring its Special Access Program. The country’s Special Access…

FridayMay 20, 2022 12:44 pm

Illinois Advocates Prepare to Introduce First Psychedelics Measure

Advocates in the state of Illinois plan to present the state’s first-ever psychedelics reform measure for approval. They have already begun educating the community on the benefits of these drugs and garnering public support. The reform measure proposes a broader decriminalization framework for a range of psychedelic substances. If the advocates are successful, they will put the state on track to adopting a framework to support the use of entheogenic medicines. The proposed measure, the Illinois Compassionate Use of Natural Plants and Fungi Act (ICUNPFA), calls for the decriminalization of the use, possession, growing, creation, production, analysis, gifting and distribution…

ThursdayMay 19, 2022 2:20 pm

Study Finds Mindfulness, Psychedelic Encounters Beneficial for Mental Well-Being

New research has discovered a positive link between the use of psychedelics, mindfulness practice and overall psychological well-being. Western University’s Tianhong Tim Qiu, the author of the study, stated that psychedelics were growing in popularity both in academic study and popular culture, noting that while most studies focused on the medical/clinical applications of these drugs as alternative therapy options for mental health conditions, users had claimed that the drugs were also beneficial to psychological well-being. The researchers’ primary objective was to find out whether ordinary individuals who used psychedelics without treatment protocols, doctor supervision and a clinical setting, could benefit…

ThursdayMay 19, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Adds Neuro-enhancing Therapies to 6 KWC Clinics, With Plans to Expand Across the Nation

Delic Holdings Corp works to develop novel solutions for hard-to-treat mental and emotional disorders The company’s Ketamine Wellness Centers (“KWC”) clinical subsidiary recently announced the addition of NAD+ (nicotinamide adenine dinucleotide) infusion therapies as a means of boosting natural energy stores and immunity, brain and DNA function, and cell communication The NAD+ therapies will launch in six of KWC’s clinics on May 9 — in Jacksonville, Fla.; Houston and Dallas, Texas; Salt Lake City, Utah; Las Vegas, Nev.; and Tucson, Ariz. KWC intends to expand the treatment to additional clinics across the country in the coming months Delic Holdings (CSE:…

WednesdayMay 18, 2022 1:48 pm

Senators Want Federal Agencies to Review Psychedelic Research

Senators Cory Booker and Brian Schatz are calling for federal agencies to provide updates on studies into the therapeutic potential of psychedelic substances. In a letter penned to the top officials at the FDA and the National Institutes on Health, the senators stated that the agencies were crucial to ensuring a rigorous and comprehensive science-based approach to research on psychedelics. The senators stated that they are encouraged that the National Institutes of Health held a workshop earlier this year to look into the regulatory challenges that are hindering research into psychedelic substances, including MDMA and psilocybin. The senators, who argued…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000